Your skin barrier is failing, and your immune system won't stop. Here's why.

Filaggrin is a structural protein that holds together the outer layer of your skin, creating a tight physical barrier. It’s the mortar between the bricks of your epidermis. Healthy filaggrin keeps water in and allergens out. It also releases natural moisturizing factors that keep skin flexible and resilient.

The FLG gene carries loss-of-function variants like R501X and 2282del4 that prevent your skin from making normal amounts of filaggrin. Roughly 10% of people with European ancestry carry these variants. When filaggrin is deficient, your skin barrier is literally more porous; allergens and irritants penetrate deeper and faster. You don’t just react to direct contact, you absorb the allergen into deeper skin layers where it triggers a more intense immune response.

This explains why your contact dermatitis doesn’t stay localized. If your filaggrin is compromised, a small patch of exposure can trigger widespread inflammation because the irritant has direct access to immune cells deeper in the skin. Healing is slower too, because your barrier can’t seal itself quickly. Each flare leaves the barrier weaker than before.

Interleukin-4 is a chemical signal released by immune cells that tells your T-cell system to bias toward allergic and Th2 responses rather than other immune pathways. It’s not inherently bad, but it’s the master switch for allergic sensitization. High IL4 signaling pushes your immune system toward making more allergic antibodies (IgE) and away from immune tolerance.

IL4 gene variants, carried by approximately 30-35% of the population, increase IL4 production or make immune cells more responsive to it. When you carry these variants, your immune system defaults to allergic response mode; you sensitize faster and to more allergens over time. Each exposure to a contact allergen doesn’t just cause an immediate reaction, it drives your immune system to remember that allergen as a threat and to amplify its response next time.

This is why your contact dermatitis spreads to new exposures over time. As your Th2 immune system becomes more dominant, you develop new sensitivities that you didn’t have before. Nickel, fragrance, preservatives; your immune system keeps adding to the list. The eczema gets worse because your immune tolerance is systematically failing.

Interleukin-13 works directly alongside IL4 to amplify allergic inflammation. While IL4 tells your immune system to go allergic, IL13 tells your skin cells to overrespond and makes the inflammatory cascade more intense. IL13 also directly damages filaggrin expression, making your skin barrier even leakier when inflammation is active.

IL13 variants, common in roughly 30-35% of the population, increase IL13 signaling. When these variants are present, your skin doesn’t just react to the allergen, it hyperinflames; filaggrin production drops further, the barrier leaks more, and immune cells stay activated longer. This creates a self-amplifying cycle: allergen gets in because the barrier is weak, triggers IL13 release, which damages filaggrin further, which lets more allergen in, which triggers more IL13. Each flare is worse than the last.

This explains the progressive worsening pattern you’re experiencing. Without genetic testing, dermatologists assume your skin is sensitizing to more allergens. What’s actually happening is that IL13 signaling is amplifying your inflammatory response to the same level of exposure you tolerated before.

The vitamin D receptor is not just about calcium absorption. VDR activation is essential for maintaining skin barrier integrity, for teaching immune cells tolerance, and for shutting down inflammatory T-cell responses. Skin cells express VDR heavily. Without active vitamin D signaling, filaggrin stays low and Th2 cells stay activated.

VDR variants like BsmI and FokI, carried by approximately 30-50% of the population, reduce receptor sensitivity or function. When you carry these variants, vitamin D signaling is less efficient; your skin barrier stays compromised and your immune system struggles to activate regulatory T-cells that suppress allergic overreaction. This means you’re fighting your contact dermatitis with both a weak barrier and weak immune brakes simultaneously. Normal vitamin D levels on a blood test don’t help, because the problem is receptor function, not vitamin D amount.

This is why many people with contact dermatitis improve dramatically when they supplement with adequate vitamin D. The dermatologist doesn’t measure it because vitamin D isn’t part of standard dermatology. But if your VDR is variant, raising your serum vitamin D to 50-60 ng/mL makes a measurable difference.

TNF-alpha is the master inflammatory cytokine. It activates the entire inflammatory cascade, recruits immune cells to affected skin, and keeps inflammation burning. High TNF-alpha is the reason why psoriasis patients respond to TNF inhibitors. It’s equally relevant to worsening contact dermatitis because TNF drives both the initial immune activation and the chronic inflammatory state that prevents healing.

The TNF gene variant -308G>A, carried by approximately 30% of European populations, increases TNF-alpha production. When you carry the A allele, your immune system produces more TNF-alpha at baseline and releases even more in response to allergen exposure; inflammation escalates faster and lingers longer. Standard dermatologic treatment never measures TNF because it’s not a routine blood test. But if your contact dermatitis is worsening despite topical steroids, elevated TNF-alpha is a likely culprit.

This explains the progressive, treatment-resistant pattern. Topical steroids suppress local inflammation temporarily, but if TNF-alpha is being overproduced systemically, flares return as soon as you stop treatment. Your immune system is running too hot to stay suppressed by topical intervention alone.

CTLA4 is a checkpoint protein on T-cells that acts as a brake. When CTLA4 engages, it tells activated T-cells to calm down, stop proliferating, and reduce inflammatory output. Without functional CTLA4 braking, T-cells stay activated longer than they should. This protein is so important that CTLA4 inhibitors are used in cancer therapy specifically because removing CTLA4 brakes unleashes T-cell response.

The CTLA4 variant +49A>G, carried by approximately 45% of the population, reduces CTLA4 function. When you carry this variant, your T-cells have weaker brakes; once activated by allergen exposure, they stay activated longer and produce more inflammatory output before finally turning off. This means your immune response to a single allergen exposure lasts longer and causes more collateral damage to surrounding skin cells.

This is why your contact dermatitis doesn’t resolve even after you’ve avoided the trigger for weeks. Your immune cells were activated by the initial allergen, but because your CTLA4 brakes are weak, they keep burning through inflammatory cycles. Each flare leaves immune cells primed and ready to respond to smaller and smaller amounts of allergen.